دورية أكاديمية
Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 – December 2019
| العنوان: | Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 – December 2019 |
|---|---|
| المؤلفون: | Merdrignac, Lore, El Belghiti, Fatima Aït, Pandolfi, Elisabetta, Acosta, Lesly, Fabiánová, Kateřina, Habington, Adele, García Cenoz, Manuel, Bøås, Håkon, Toubiana, Julie, Tozzi, Alberto E., Jordan, Iolanda, Zavadilová, Jana, O'Sullivan, Niam, Navascués, Ana, Flem, Elmira, Croci, Ilena, Jané, Mireia, Křížová, Pavla, Cotter, Suzanne, Fernandino, Leticia, Bekkevold, Terese, Muñoz-Almagro, Carmen, Bacci, Sabrina, Kramarz, Piotr, Kissling, Esther, Savulescu, Camelia, Renacoq Group, The PERTINENT Group |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2024 |
| المجموعة: | UIC Open Access Archive (Universitat Internacional de Catalunya) |
| مصطلحات موضوعية: | Tos ferina, Vacuna contra la tos ferina, Efectivitat de la vacuna, Vigilància hospitalària, Eficacia de la vacuna, Vigilancia hospitalaria, Pertussis, Whooping cough, Pertussis vaccine, Vaccine effectiveness, Hospital surveillance |
| الوقت: | 61 |
| الوصف: | Background: Monitoring effectiveness of pertussis vaccines is necessary to adapt vaccination strategies. PERTINENT, Pertussis in Infants European Network, is an active sentinel surveillance system implemented in 35 hospitals across six EU/EEA countries. We aim to measure pertussis vaccines effectiveness (VE) by dose against hospitalisation in infants aged <1 year. Methods: From December 2015 to December 2019, participating hospitals recruited all infants with pertussis-like symptoms. Cases were vaccine-eligible infants testing positive for Bordetella pertussis by PCR or culture; controls were those testing negative to all Bordetella spp. For each vaccine dose, we defined an infant as vaccinated if she/he received the corresponding dose >14 days before symptoms. Unvaccinated were those who did not receive any dose. We calculated (one-stage model) pooled VE as 100*(1-odds ratio of vaccination) adjusted for country, onset date (in 3-month categories) and age-group (when sample allowed it). Results: Of 1,393 infants eligible for vaccination, we included 259 cases and 746 controls. Median age was 16 weeks for cases and 19 weeks for controls (p < 0.001). Median birth weight and gestational age were 3,235 g and week 39 for cases, 3,113 g and week 39 for controls. Among cases, 119 (46 %) were vaccinated: 74 with one dose, 37 two doses, 8 three doses. Among controls, 469 (63 %) were vaccinated: 233 with one dose, 206 two doses, 30 three doses. Adjusted VE after at least one dose was 59 % (95 %CI: 36–73). Adjusted VE was 48 % (95 %CI: 5–71) for dose one (416 eligible infants) and 76 % (95 %CI: 43–90) for dose two (258 eligible infants). Only 42 infants were eligible for the third dose. Conclusions: Our results suggest moderate one-dose and two-dose VE in infants. Larger sample size would allow more precise estimates for dose one, two and three. ; info:eu-repo/semantics/publishedVersion |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0264-410X |
| العلاقة: | Vaccine; 42;9; Merdrignac, Lore El Belghiti, Fatima Aït Pandolfi, Elisabetta [et al.]. Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 – December 2019. Vaccine, 2024, 42(9), p. 2370-2379. Disponible en: . Fecha de acceso: 5 abr. 2024. DOI:10.1016/j.vaccine.2024.02.090; http://hdl.handle.net/20.500.12328/4186Test; https://dx.doi.org/10.1016/j.vaccine.2024.02.090Test |
| DOI: | 10.1016/j.vaccine.2024.02.090 |
| الإتاحة: | https://doi.org/20.500.12328/4186Test https://doi.org/10.1016/j.vaccine.2024.02.090Test https://hdl.handle.net/20.500.12328/4186Test |
| حقوق: | © 2024 The Author(s). Published by Elsevier Ltd. ; http://creativecommons.org/licenses/by/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.95DE241D |
| قاعدة البيانات: | BASE |
| تدمد: | 0264410X |
|---|---|
| DOI: | 10.1016/j.vaccine.2024.02.090 |